NANOBIOTIX (EPA:NANO)

PRESS RELEASE

published on 11/13/2025 at 22:15, 2 months 16 days ago

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Nanobiotix announces advancements in Curadigm Nanoprimer platform with new patent applications, pre-clinical data, and external collaborations, aiming to revolutionize drug delivery

Pre-clinical Data Patent Applications NANOBIOTIX Curadigm Nanoprimer External Collaborations
BRIEF

published on 11/11/2025 at 22:20, 2 months 18 days ago

Nanobiotix will participate in the Jefferies London Healthcare conference

Biotechnology Oncology NANOBIOTIX Nanoparticles Jefferies Conference
PRESS RELEASE

published on 11/11/2025 at 22:15, 2 months 18 days ago

NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Nanobiotix to participate in Jefferies London Healthcare Conference on Nov 17, 2025, with company management as presenters. Webcast available. Learn about Nanobiotix and its disruptive therapeutic approaches

Webcast Nanotechnology NANOBIOTIX Therapeutic Approaches Jefferies London Healthcare Conference
BRIEF

published on 10/31/2025 at 08:05, 2 months 30 days ago

Nanobiotix Secures $71 Million Agreement with HealthCare Royalty

Long-term Growth HealthCare Royalty NANOBIOTIX Royalty Agreement Oncology Development
PRESS RELEASE

published on 10/31/2025 at 08:00, 2 months 30 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix announces $71M strategic royalty monetization agreement with Healthcare Royalty, extending cash runway and enabling long-term growth in cancer treatment

Cancer Treatment HealthCare Royalty Financial Agreement NANOBIOTIX Royalty Monetization
BRIEF

published on 10/01/2025 at 22:20, 3 months 28 days ago

NANOBIOTIX Reveals Promising Phase 1 Study Results for Esophageal Cancer Treatment

Phase 1 Study Radiotherapy Adverse Events JNJ-1900 (NBTXR3) Esophageal Cancer
PRESS RELEASE

published on 10/01/2025 at 22:15, 3 months 28 days ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
BRIEF

published on 09/30/2025 at 22:20, 3 months 29 days ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900
PRESS RELEASE

published on 09/30/2025 at 22:15, 3 months 29 days ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix provides business update & reports 2025 half year financial results. Highlights clinical development program & financial performance

Financial Results Financial Performance Business Update Clinical Development NANOBIOTIX
BRIEF

published on 09/30/2025 at 00:35, 4 months ago

NANOBIOTIX Reports Promising Phase 1 Results for JNJ-1900 (NBTXR3) in R/M-HNSCC

Phase 1 Trial NANOBIOTIX Clinical Study Results R/M-HNSCC JNJ-1900 (NBTXR3)

Published on 01/30/2026 at 14:00, 59 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 6 hours 24 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 6 hours 59 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 12 hours 44 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 14 hours 59 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 14:11, 48 minutes ago

SBF AG expects stable to positive business development in a challenging environment for 2026
Published on 01/30/2026 at 13:30, 1 hour 29 minutes ago

North Peak Expands Wabash Gold Mineralization at Prospect Mountain, Nevada
Published on 01/30/2026 at 12:00, 2 hours 59 minutes ago

HSBC UK and Sage simplify tax reporting for small businesses ahead of Making Tax Digital
Published on 01/30/2026 at 11:54, 3 hours 5 minutes ago

EQS-Adhoc: YOC AG: PRELIMINARY FIGURES FOR THE 2025 FINANCIAL YEAR
Published on 01/30/2026 at 10:30, 4 hours 29 minutes ago

ASTA ENERGY SOLUTIONS AG SUCCESSFULLY COMPLETES IPO

View all EQS

Published on 01/30/2026 at 08:00, 6 hours 59 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 20 hours 59 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 21 hours 14 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 21 hours 14 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 21 hours 19 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News